high mobility group nucleosomal binding domain 2 pseudogene 30Genealiases: []
Q-omics provides the consensus-scored HMGN2P30 profile across patient tissues and cancer cell-line models. HMGN2P30 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HMGN2P30 is differentially expressed in 4, with the highest sampling consensus in THCA. Additionally, HMGN2P30 RNA expression shows 9,187 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, THCA, and PDAC as cancer lineages where HMGN2P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN2P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN2P30 survival associations across molecular data types. HMGN2P30 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN2P30 RNA expression–survival associations across cancer types. High HMGN2P30 expression shows unfavorable associations in KIRC and ACC, but favorable associations in LUAD, BRCA, UCS and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HMGN2P30 RNA expression.
This table summarizes HMGN2P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN2P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN2P30 shows lower tumor expression in THCA and LUSC and higher tumor expression in BRCA and COAD. The THCA box plot shows higher HMGN2P30 RNA expression in normal versus tumor tissue (log2 FC = −0.146, t-test p = .003).
This table shows molecular features associated with HMGN2P30 in patient tissues and cancer cell lines. In patient samples, HMGN2P30 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
